Company Description
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions.
The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform.
Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma.
The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer.
Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
| Country | United States |
| Founded | 2017 |
| IPO Date | Apr 30, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 46 |
| CEO | Daniel Hicklin |
Contact Details
Address: 200 Talcott Ave, 2nd Floor Watertown, Massachusetts 02472 United States | |
| Phone | 617 952 0555 |
| Website | werewolftx.com |
Stock Details
| Ticker Symbol | HOWL |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001785530 |
| CUSIP Number | 95075A107 |
| ISIN Number | US95075A1079 |
| Employer ID | 82-3523180 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Daniel J. Hicklin Ph.D. | Founder, Chief Executive Officer, President, Secretary and Director |
| Timothy W. Trost CPA | Chief Financial Officer, Treasurer and Assistant Secretary |
| Dr. Randi Isaacs M.D. | Chief Medical Officer |
| Dr. William Winston Ph.D. | Senior Vice President of Research |
| Dr. Chulani Karunatilake Ph.D. | Chief Technology Officer |
| Steven H. Bloom R.Ph. | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 13, 2025 | 8-K | Current Report |
| May 15, 2025 | EFFECT | Notice of Effectiveness |
| May 15, 2025 | 8-K | Current Report |
| May 14, 2025 | SCHEDULE 13D/A | Filing |
| May 12, 2025 | UPLOAD | Filing |
| May 8, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| May 8, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 8, 2025 | 10-Q | Quarterly Report |
| May 8, 2025 | 8-K | Current Report |
| Apr 28, 2025 | ARS | Filing |